Viewing data from:

TEKAMLO

NDA

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE | N022545 | NOVARTIS PHARMACEUTICALS CORP

4 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2027

2028

2029

2030

Today

Dec. 21, 2029

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

13 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — EQ 150MG BASE;EQ 5MG BASE

1 patent0 exclusivities▴

TABLET;ORAL | Approved: Aug 26, 2010

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8613949	Dec 21, 2029	—	—	Yes	—	—

#002 — EQ 150MG BASE;EQ 10MG BASE

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Aug 26, 2010

#003 — EQ 300MG BASE;EQ 5MG BASE

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Aug 26, 2010

#004 — EQ 300MG BASE;EQ 10MG BASE

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Aug 26, 2010